Arcutis Biotherapeutics, Inc. (ARQT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Arcutis Biotherapeutics, Inc.
Address
3027 Townsgate Road
Westlake Village, CA 91361
United States of America (the)
Phone
805 418 5006
Website
Sector
Healthcare
Industry
Biotechnology
Employees
342
First IPO Date
January 31, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Todd Franklin Watanabe | President, Chief Executive Officer & Director | 1.31M | 1968 |
| Bhaskar Chaudhuri | Co-Founder & Director Emeritus | 60,054 | 1955 |
| Bethany Dudek | Chief Technical Officer | 584,551 | N/A |
| Latha Vairavan | Senior Vice President & Chief Financial Officer | 644,904 | 1978 |
| Masaru Matsuda | Executive VP, Chief Legal Officer & Corporate Secretary | 787,699 | 1971 |
| Patrick E. Burnett | Executive Vice President & Chief Medical Officer | 883,376 | 1972 |
| L. Todd Edwards | Executive Vice President & Chief Commercial Officer | 897,205 | 1964 |
| Douglas DiRuggiero DMSC | Advanced Practitioner | 0 | N/A |
| Jeff Kiekhofer | VP & Controller | 0 | N/A |
| Rajvir Madan | Chief Digital & Technology Officer | 0 | N/A |
| Steve Arias | Vice President of Compliance & Privacy | 0 | N/A |
| Amanda Sheldon | Head of Corporate Communications | 0 | N/A |
| Brian Schoelkopf | Head of Investor Relations | 0 | N/A |
| Aleen Hosdaghian | Vice President of Marketing | 0 | N/A |
Description
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
